SecBot SecBot
Biotech Drug Report Generated Oct 28, 2026

SKYCLARYS

BIIB·BIOGEN INC.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed in the US (February 2023) and EU (February 2024). Pediatric label expansion, if successful, would follow the BRAVE study readout, likely in 2028 or later.
Why 4/10
SKYCLARYS is already approved and commercializing with no pending PDUFA or pivotal readout in the next ~12 months. The Phase 3 BRAVE pediatric study completed enrollment in August 2026, but its 52-week primary endpoint means results are unlikely before late 2027. As a marketed product within Biogen's diversified portfolio, SKYCLARYS drives steady commercial growth but lacks a near-term binary catalyst.
Actionable Insight NEUTRAL

SKYCLARYS has no upcoming PDUFA or pivotal readout in the next 12 months. The Phase 3 BRAVE pediatric study (ages 2-15) completed enrollment in August 2026, but its 52-week primary endpoint means topline results are unlikely before late 2027. Watch for quarterly sales growth trajectory and any label-expansion updates from the BRAVE study as the next potential catalysts.

Price Chart

Loading chart...

Executive Summary

SKYCLARYS (omaveloxolone) is the first and only FDA-approved treatment for Friedreich's ataxia (FA), a rare neurodegenerative disease. Originally developed by Reata Pharmaceuticals and acquired by Biogen, it was approved by the FDA in February 2023 and by the European Commission in February 2024 for patients aged 16 and older. The drug is a key growth driver for Biogen, posting Q3 2026 revenue of $178.2 million (+34% year-over-year). With no pending regulatory decision or near-term binary catalyst, SKYCLARYS is a steady commercial-stage asset within Biogen's diversified portfolio.

How It Works

SKYCLARYS is a once-daily oral pill that activates the Nrf2 pathway, a protein the body uses to reduce oxidative stress and inflammation. In Friedreich's ataxia, cells are damaged by oxidative stress, and this drug helps protect nerve cells by boosting the body's natural defense system.

Trial Status

SKYCLARYS was approved by the FDA in February 2023 based on the Phase 2 MOXIe study (NCT02255435), a 48-week randomized, double-blind, placebo-controlled trial in 103 patients aged 16-40. The drug is now commercially available in the US and EU. Biogen is conducting the Phase 3 BRAVE study (NCT06953583) in pediatric patients aged 2-15, which completed enrollment ahead of schedule in August 2026. A Phase 1 BOLD study for pediatric dosing is also ongoing.

The Two-Sided Case

▲ Bull Case5
First and only approved treatment for Friedreich's ataxia, a rare disease with high unmet need and no direct competitors
Strong commercial momentum: Q3 2026 revenue of $178.2 million (+34% year-over-year), making it a key growth driver for Biogen
Pediatric expansion via the Phase 3 BRAVE study could significantly expand the addressable patient population if successful
Patent protection until approximately 2033 provides a long exclusivity runway
European approval (February 2024) and recent Irish HSE reimbursement (August 2026) expand geographic reach
▼ Bear Case5
Already approved with no near-term binary catalyst, limiting upside from this drug alone for Biogen's stock
Biogen is a diversified company (Leqembi, Spinraza, MS franchise, Apellis products) so SKYCLARYS is one of several growth drivers, diluting its impact on the stock
The BRAVE pediatric study results are likely 12+ months away, providing no imminent catalyst
Friedreich's ataxia is an ultra-rare disease (estimated ~5,000 patients in the US), capping peak revenue potential
Potential competition from other FA pipeline programs (gene therapies, vatiquinone) could emerge in coming years

Upcoming Catalysts

  • Phase 3 BRAVE pediatric study topline results (estimated late 2027, 52 weeks after August 2026 enrollment completion)
  • Quarterly sales reports as a key growth-portfolio metric for Biogen

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BIOGEN INC. 8-K BIIB ·Originating report

Sources · 13

Hover a chip for the title
1 en.wikipedia.org2 fda.gov3 accessdata.fda.gov4 investors.biogen.com5 accessdata.fda.gov6 investors.biogen.com7 ataxia.org8 x.com9 marketscreener.com10 curefa.org11 clinicaltrials.gov12 pharsight.greyb.com13 sec.gov